Aurobindo Pharma’s subsidiary TheraNym has signed a master service agreement with pharma major Merck Sharpe & Dohme Singapore Trading (MSD) for contract manufacturing of biologicals.

TheraNym, which will manufacture the products and supply to MSD, intends to invest about Rs 1,000 crore for establishing a manufacturing facility with large scale bioreactors, for any mammalian cell culture product and a vial filling isolator line for commercial drug product manufacturing upto 25-30 mn vials per annum.

The agreement is for expansion of the biologics manufacturing facilities of TheraNym in Medak district of Telangana, and to explore entering into contract manufacturing operations for both domestic and international markets.

It aligns with the company's goal of expanding capabtlities in biologicals manufacturing. The plant will be equipped with technology, and standards of quality and efficiency. Both companies aim to drive innovation and deliver these products.